Provided by Tiger Fintech (Singapore) Pte. Ltd.

INNOVENT BIO

79.300
+0.9001.15%
Volume:29.39M
Turnover:2.36B
Market Cap:131.08B
PE:-1.25K
High:82.350
Open:80.000
Low:78.000
Close:78.400
Loading ...

Innovent Biologics Logs 40% Boost in Q1 Product Revenue

MT Newswires Live
·
02 May

BUZZ-Innovent Biologics rises on robust Q1 product revenue growth

Reuters
·
02 May

BRIEF-Innovent Biologics Says Qtrly Achieved Total Product Revenue Exceeding RMB2.4 Billion

Reuters
·
01 May

Innovent Biologics - Qtrly Achieved Total Product Revenue Exceeding RMB2.4 Bln

THOMSON REUTERS
·
01 May

Innovent Announces First Patient Dosed in Phase 1 Study of Ibi3020, Global First-in-Class Dual Payload Ceacam5 ADC, in Patients With Advanced Malignancies

THOMSON REUTERS
·
30 Apr

Innovent Biologics Inc. Releases Environmental, Social and Governance Report

Reuters
·
29 Apr

Innovent Biologics Inc. Publishes 2024 Annual Report

Reuters
·
29 Apr

Innovent Announces Nmpa Approval of Limertinib, a Third-Generation Egfr Tki Collaborated With Ask Pharma, for the First-Line Treatment of Lung Cancer

THOMSON REUTERS
·
26 Apr

BRIEF-Innovent Biologics Says Third-Generation EGFR TKI Limertinib Received Approval From NMPA

Reuters
·
25 Apr

Innovent Biologics - Third-Generation Egfr Tki Limertinib Received Approval From Nmpa

THOMSON REUTERS
·
25 Apr

High Growth Tech Stocks In Asia For April 2025

Simply Wall St.
·
15 Apr

Stock Track | Innovent Biologics Soars 18.95% Following Strong 2024 Financial Results

Stock Track
·
27 Mar

Stock Track | Innovent Biologics Soars Nearly 19% on Impressive 2024 Financial Results

Stock Track
·
27 Mar

Innovent Bio's 2024 Loss Narrows as Revenue Surges 52%; Shares Jump 14%

MT Newswires Live
·
27 Mar

BRIEF-Innovent Announces 2024 Annual Results And Business Updates

Reuters
·
26 Mar

Innovent Announces 2024 Annual Results and Business Updates

THOMSON REUTERS
·
26 Mar

Press Release: Innovent Announces 2024 Annual Results and Business Updates

Dow Jones
·
26 Mar

Innovent Biologics FY Adjusted Net Income RMB 331.6 Million

THOMSON REUTERS
·
26 Mar

Hutchmed, Innovent Combo Therapy Hits PFS Target in Renal Cancer Study

MT Newswires Live
·
19 Mar

Hutchmed (China) Says Frusica-2 Phase II/III Study Met Primary Endpoint

Reuters
·
19 Mar